Objectives: Alzheimer's disease (AD) affects people worldwide, and the prevalence is increasing as the population ages. There is an international effort to understand the biology of AD to develop primary and secondary prevention strategies, and to develop effective therapeutic interventions for individuals who are already symptomatic. One of the critically important pieces of all national plans to address AD is the call for the development of service models to deliver quality, effective care based on the best evidence available. 
Introduction
There were an estimated 36 million people worldwide living with dementia in 2010, primarily Alzheimer's disease (AD) [1, 2] . The number of cases, in both absolute and relative terms, is expected to increase substantially as the population continues to age, in some cases tripling during the next 25 years [3] . As a consequence, there is an increasing international effort to understand the biology of AD to develop primary and secondary prevention strategies, as well as to develop effective therapeutic interventions for individuals who are already symptomatic. In response to these needs, the U.S. government passed the National Alzheimer's Project Act on January 4, 2011 [4] , which required the secretary of the U.S. Department of Health and Human Services to establish the National Alzheimer's Project to create and maintain an integrated national plan to overcome AD; to coordinate AD research and services across all federal agencies; to accelerate the development of treatments that would prevent, halt, or reverse the course of AD; to improve early diagnosis and coordination of care and treatment of AD; to improve outcomes for ethnic and racial minority populations that are at higher risk for AD; and to coordinate with international bodies to fight AD globally.
At the same time as the National Alzheimer's Project was being developed, a special subcommittee on aging of the U.S. Senate released its report comparing international approaches to AD and dementia [3] . The subcommittee reached several conclusions based on their analysis. First, medical professionals "do not and cannot always properly diagnose" AD (pg. 85). Second, there is an international effort to develop home-and community-based services within existing health care delivery systems so that individuals with dementia can remain in their own home for as long as possible. Third, as a consequence of this desire to preserve autonomy in individuals with dementia, the committee noted the challenge of providing coordinated and integrated care, particularly among those patients with a more severe form of dementia. Last, the subcommittee examined the role of family members as the primary care providers to individuals with dementia. Thus, it is clear there are both regional and international efforts to address the underlying causes of AD and dementia, its diagnosis, treatment, and the development of services and support mechanisms.
One of the critically important pieces of the National Alzheimer's Project was the call for the development of service models, and to develop methods to deliver high-quality, effective care based on the best available evidence of efficacy. This is similar to what is already being done in other countries, and mirrors the call that was made by the Psychogeriatric Advisory Council to the Health Service of Catalonia (Spain; Cognitive and Behavioral Disorders in Social Health Care) in 1998 to develop "concrete strategies and action[s] aimed at improving the diagnosis, evaluation and monitoring of the people affected" (p. 101 [5] ). Indeed, many countries in Europe now have national dementia strategies or are committed to developing such strategies [6] , and two of these (Britain, France) were part of the analysis conducted by the Senate Subcommittee on Aging.
There are a variety of model systems in place around the world that provide a range of care services, each of which model reflects the local cultural norms as well as government and legal restrictions and expectations. A common thread in all the discussions regarding research and services in AD and related dementias is the need for coordination of activities. Indeed, a coordinated site for providing clinical services in a patient-and family-centered environment can provide the backbone onto which coordinated clinical and basic research can be placed. Fundaci o ACE, Institut Catal a de Neuroci ences Aplicades (Fundaci o ACE) has developed one type of integrated care model in Barcelona (Spain) that includes diagnosis, therapy, follow-up care, daycare, and a day hospital, and does so in the context of an active clinical research program. The Alzheimer's Education Center (ACE) was established in 1991 and has evolved based on the changing needs and demands of the patients and their families, and based on changing evidence-based therapies and management techniques. There are proposed frameworks for comprehensive clinical and research settings for AD and related dementias in the United States [7] ; however, we describe the organization and inner workings of Fundaci o ACE, which has been in operation in Spain for more than 15 years.
Fundaci o ACE began the Memory Clinic in 1996 with the goal of addressing the increasing demand for the treatment and education for those individuals with dementia, and to do so by offering personal attention to the patients and their families. What began solely as a day center evolved to include the Memory Clinic that now has a new 10-year contract with the Health Ministry of the Government of Catalonia, guaranteeing the services of the clinic through 2022. In addition to providing services through the health system, Fundaci o ACE also provides care on a fee-forservice basis.
The structure of Fundaci o ACE
Fundaci o ACE evolved an organizational structure that allows it to meet the needs of patients, families, professionals, and researchers, and to respond to changes in these needs over time. Details of the structure are presented in the supplemental material, but, in brief, the center is divided into five interacting groups that are managed by an administrative team that is responsible for financial oversight, communication among the other seven teams, and communications with external collaborators. The outreach team consists of a full-time coordinator as well as independent contractors who provide a comprehensive website and a monthly electronic magazine, and who manage teaching activities and international conferences. The Memory Disorders Unit is similar to the clinical core of many of the AD research centers in the United States. It is structured as a referral center and receives patients from districts of greater Barcelona, supported by the Health Ministry, as well as private patients. The unit includes neurologists, geriatricians, neuropsychologists, social workers, nurses, and clinical and technical staff.
There is a continuity of care team that works with the patients through the therapeutic day center. The center serves as an alternative to hospitalization or institutionalization; there is a daycare facility for people with late-onset dementia, and a day hospital for people with early-onset dementia. The daycare services group is designed to enhance, preserve, and promote the independence of patients in their basic activities of daily living and to reduce caregiver burden. The team includes a medical director, an assistant manager, a center coordinator, a hospital coordinator, neurologists, a geriatrician, psychiatrists, neuropsychologists, psychologists, social workers, nurses, clinical assistants, occupational therapists, physical therapists, and health care aides.
There is a team devoted specifically to research, which includes brain imaging and clinical and basic research, including genetics, bioinformatics, and clinical trials. The neuroimaging group manages the first-line clinical neuroimaging modality (i.e., computerized axial tomographic scanning) as well as research-level imaging procedures that are parts of clinical trials and other funded research (e.g., magnetic resonance imaging, single photon emission computed tomography, positron emission tomography). A clinical trials team carries out studies funded by the pharmaceutical industry. The bioinformatics group is comprised of data management and biostatistics teams, including data managers and doctoral-level biostatisticians and physicists, a doctoral-level psychologist as well as information technology consultants who build and maintain the computer infrastructure for Fundaci o ACE, and who work to design experiments and analyze data from the researchers. Last, there is a basic research group that focuses on genetics.
Fundaci o ACE has a laboratory that facilities that processing of samples from all newly enrolled patients so the foundation can participate in genomewide association studies as well as biomarker studies.
All patients undergo standardized neurobehavioral examinations, including neuropsychological [8] and social work evaluations, as well as appropriate laboratory and neuroimaging studies. All diagnoses are assigned by the clinical team at a daily consensus conference. The diagnosis of AD is based on the National Institute of Neurological and Communicative Disorders and StrokeAlzheimer's Disease and Related Disorders Association criteria [9] ; standard research-level diagnostic criteria are used for the classification of vascular dementia [10, 11] , frontotemporal dementia [12, 13] , Lewy body dementia [14] , Parkinson's disease [15] , and other relevant conditions affecting cognition in the elderly (e.g., depression using Diagnostic and Statistical Manual of Mental Disorders, fourth edition [16] ).
Mild cognitive impairment (MCI) is classified in terms of amnestic and nonamnestic MCI by using the current criteria [17, 18] , and requires the presence of measurable alterations in cognitive functions not sufficient to warrant diagnosis of dementia. Patients (or their caregivers) must report alterations in memory and/or cognition, but there can be no decline in general intellectual abilities.
However, the diagnostic criteria for MCI within the center changed during the past 15 years. Prior to 2006, patients who would have later met the criteria for MCI were classified as having age-related cognitive impairment, age-related memory impairment, or MCI (using the 1999 criteria [17] ). From 2006 onward, the center used the current research criteria [18, 19] and added the additional qualifiers of probable (i.e., uncomplicated by concomitant medical conditions) and possible (i.e., with an associated medical condition that could account for the impairment) [20] . Patients were further differentiated by the presence or absence of a memory deficit.
Patients are referred to the Memory Clinic by their primary care physician, a consulting neurologist, or a psychiatrist, for example. There is an initial interview by the social worker with the family (40 minutes) followed by an interview of the family by the neurologist (30 minutes) and a neurological examination of the patient (30 minutes). A neuropsychological evaluation (50 minutes) follows, and the results are collated for presentation at the next day's consensus conference (w10-15 minutes per patient) (see Supplemental Table E-1). The final diagnosis using established research-level criteria (mentioned earlier) is based on the results of the neurological, neuropsychological, and social work valuations. A therapeutic plan is developed that can include pharmacological and nonpharmacological therapies, as well as access to social resources. A second appointment is scheduled, at which time the family and patient are informed of the diagnosis and therapeutic options are discussed (30 minutes).
For follow-up visits, a similar sequence is used, but the neurological examination is more focused (30 minutes) and the families spend the time with the social worker (30 minutes); the neuropsychological evaluation is repeated in its entirety (50 minutes). For those patients who are supported by the Catalan Health Service, funds are provided to support the three components of the visit. Of those patients whose dementia has progressed to a moderate-severe stage (i.e., a Clinical Dementia Rating 2 points), the neuropsychological evaluation is replaced by a more extensive social work interview (i.e., w80 minutes) to provide additional support to the patient and family. For private-pay patients (including those with private insurance policies), a similar plan is used (i.e., private pay does not result in additional attention or services).
The growth of Fundaci o ACE
A total of 13,048 patients enrolled in Fundaci o ACE from 1996 through December 2011. The annual rate of examinations increased to 1773 in 2011 from 390 in 1996; the cumulative number of all patients enrolled in the center is shown in Figure 1 . Figure 2 shows the cumulative totals of the patients with AD and MCI. Table 1 shows the basic characteristics of the patients broken down into summary diagnostic groups. A group of cognitively normal elderly subjects was recruited into a research project [21] , and provides important comparative information. There are significant differences in age (F [6, 11, Women were more common than men in all groups (P , .05). The patients without cognitive impairment were younger than those with cognitive disorders (least significant difference test, P , .05). The characteristics of the MCI patients who entered after 2005 are shown in Table 2 .
The number of follow-up visits increased to 3579 in 2011 (a total of 5532 evaluations) from 256 in 1997 (65% of new patients). The median number of years of followup for all patients through 2011, from entry until their last visit, is 2.85 years (95% confidence interval, 2.78-2.92). Because the rate of enrollment is increasing, the median follow-up does not reflect the whole picture. For the patients enrolled in 2001, who had 10 years of possible follow-up, the mean time as a clinic patient is 6.98 6 2.65 years. For those who enrolled in 2006, who have only 5 years of possible follow-up, the mean time as a clinic patient is 3.68 6 1.89 years.
At least one follow-up visit was available for the 1396 patients who were initially classified with MCI after 2005. Seventy-three percent of the probable MCI patients developed AD during follow-up, and 51% of the possible MCI patients developed dementia. Nonamnestic MCI evolved into clinical dementia in 33% of the patients.
Discussion
Fundaci o ACE has provided diagnosis, management, daycare, and day hospital facilities for the citizens in the catchment area around the city center of Barcelona since 1996. The primary diagnosis identified among the more than 13,000 patients was probable AD, accounting for 47% of the patients with cognitive disorders. MCI accounted for a further 30% of individuals, and approximately 15% of all patients referred for evaluation were classified as having subjective complaints of cognitive impairment with no objective findings.
Fundaci o ACE can serve as a model system to be adapted to other settings within local cultural, government, and legal constraints. Any new service models developed as a consequence of the National Alzheimer's Project, for example, must be flexible enough to adapt to both short-term and long-term changes in the needs of the patients and families. One of the important differences between the plans outlined in the 1998 Catalan and the 2012 U.S. the National Alzheimer's Project was the relative emphasis on families and on institutional care. Reliance on informal family caregivers likely reflects not only the (un)availability of a formal services, but also cultural norms [3] . Thus, although the United States places greater emphasis on group or institutional care (while paradoxically not providing adequate funding), countries such as Spain rely more heavily on families to care for the ill and infirm. This is reflected in the organization and operation of Fundaci o ACE. In addition to day hospital services for individuals with memory complaints or mild dementia (which also serves as respite care for caregivers), Fundaci o ACE also offers educational services and specialized information to the families of the patients free of charge. The foundation's professional educational efforts focus on the geriatricians, neurologists, and psychiatrists who are the initial point of contact for the patients and families, and who make the initial referrals to the Memory Clinic, and who are responsible for many aspects of the general health care of the patients.
The integration of the diagnosis and management of patients with cognitive disorders is facilitated by the organization of the health care system in Spain. To be enrolled in a dementia clinic such as that at Fundaci o ACE, the patients must be referred by their primary care provider or a consulting physician, who is responsible for parts of the initial evaluation, including laboratory studies and brain imaging. However, the neurological examination, psychiatric evaluation, social work assessment, and neuropsychological evaluation are all completed as part of the work of the Memory Clinic. The information from these specialty examinations and the resulting diagnoses (with recommendations) are passed back to the primary physician, who is responsible for the total care of the patient's health. However, therapy (especially pharmacotherapy) is the responsibility of Fundaci o ACE.
From a research perspective, the patients enrolled and followed in Fundaci o ACE provide a unique window into the characteristics of patients with dementia syndromes because they are typically seen in clinical care. Unlike research centers that focus on the identification of participants with few if any medical complications (because they are needed for pharmaceutical trials), Fundaci o ACE enrolls all-comers. As such, the research team is in a position to confirm and extend findings from tertiary care research centers in a more clinically diverse population. Furthermore, as the number of Fundaci o ACE patients who are genotyped increases, it will be possible to examine the relative impact of various newly identified single nucleotide polymorphisms and their role in modifying risk for sporadic AD [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Indeed, the patients from Fundaci o ACE serve as an excellent confirmation sample because they have not provided their genetic material to other studies, and thus the data are entirely independent of other genomewide association studies.
Fundaci o ACE provides a good, working model for integrated care in dementia. From the initial point of contact, patients and their families have a range of services that are offered to them by the Health Service through Fundaci o ACE, including pharmacological and nonpharmacological therapeutic interventions, daycare, and a day hospital [32, 33] . The availability of patient-centered day services, especially those that provide respite for families and stimulation for patients, could potentially extend the period of higher quality of life, thus meeting one of the primary goals of the care of patients with AD and related dementias.
One of the principal differences between the care model implemented in Fundaci o ACE and those used more commonly in the United States and other countries is the lack of a comprehensive approach to the care of the patients and their families in these other settings. As noted by the Senate Subcommittee on Aging [3] , care of demented patients tends to be fragmented, whereas in Fundaci o ACE, care and management is more fully integrated. We are not aware of other clinics with this kind of integrated system that are generally open and available to all people in need, regardless of their ability to pay.
The World Health Organization has recommended that priority should be given to dementia research as a public health agenda [34] , a call that is reminiscent of a proposal made in 2006: "Epidemiological surveillance is an essential instrument for planning, managing and distributing community health resources, for following up the natural history of chronic diseases and for assessing the impact of programmes of prevention" [35] . Fundaci o ACE is able to integrate z Percent (n) female.
x Percent (n) with at least one copy of the ε4 allele. Total with APOE genotyping is 308. research into the context of providing care, not only by supporting intervention trials, but also by the use of the patient database to provide insight into the natural and treated history of AD and related dementias. Lopez-Pousa and colleagues [35] outlined a simple, minimal (i.e., 36-item) data set that could significantly advance our understanding of AD and related dementias, and this was shown to be a viable method for obtaining information about the prevalence and characteristics of dementia [36] . This kind of data could then be used to study intra-and interregional trends, and might be of particular use in resource-limited areas. An effort such as this would require the cooperation of scores of facilities and would require sufficient funding to support an independent data management and analysis system. However, there could be "a sequential implementation of the registry . so that it can be adapted to each health district or region" [35] . Thus, as we have emphasized regarding the development of the Fundaci o ACE clinical services, such a registry must be allowed to evolve, with the specific national, regional, and local variations to allow for the acquisition of relevant data. The goal of this article was to describe the workings of an existing AD care center that seems to meet many of the requirements specified by the National Alzheimer's Project and by other international efforts to address AD and related dementias. What we cannot report is a cost-benefit analysis or an econometric modeling of the services provided by Fundaci o ACE. Not only is this beyond our expertise and our available data, but the results likely would not generalize to other regions or countries with different health and social services, and different cultural expectations. However, we believe that Fundaci o ACE is able to deliver the services that are suggested by the various national plans, and it does so in a cost-efficient manner.
The U.S. National Alzheimer's Project acknowledges: "Many nations have developed Alzheimer's plans of their own that involve improved care and supports for people with Alzheimer's disease and their caregivers, as well as enhanced research and public awareness. In implementing the actions in this plan, [Health and Human Services] and its federal partners will coordinate with global partners to enhance these plans, avoid duplication of effort, and optimize existing resources" (p. 30 [4] ). The experience of Fundaci o ACE has much to contribute to these efforts. The specific methods and organization of Fundaci o ACE are likely not generalizable to all parts the world; but, the success of Fundaci o ACE shows that a model of integrated, patient-centered care with a built-in research emphasis, can be used elsewhere. Each center must evolve based on regional constraints and on the needs of the patients, their families, and the professionals who care for them. establish the National Alzheimer's Project to create and maintain an integrated national plan to overcome Alzheimer's disease (AD). One of the critically important pieces of this project is the call for the development of service models, and to develop methods that are used to deliver high-quality, effective care based on the best available evidence of efficacy.
2. Interpretation: This report describes the workings of an existing AD care center in Spain that seems to meet many of the requirements specified by the National Alzheimer's Project and by other international efforts to address AD and related dementias.
3. Future Directions: The specific methods and organization of the center are likely not generalizable to all parts the world; however, the success of the center shows that a model of integrated, patient-centered care, with a built-in research emphasis, can be used.
